Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-κB in rats with TNBS-induced colitis

Journal of Nutritional Biochemistry

Volumn 24, Issue 4, 2013, Pages 700-705

  Mbodji, Khaly ^a   Charpentier, Cloé ^a,b   Guérin, Charlène ^a   Querec, Coraline ^a   Bole Feysot, Christine ^a   Aziz, Moutaz ^b   Savoye, Guillaume ^a,b   Déchelotte, Pierre ^a,b   Marion Letellier, Rachel ^a  

^a Faculté de Médecine Pharmacie   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

5 ASA; Colitis; Inflammation; N 3 PUFA

Indexed keywords

CYCLOOXYGENASE 2; FISH OIL; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTRALIPID; LEUKOTRIENE B4; MESALAZINE; MESSENGER RNA; OMEGA 3 FATTY ACID; OMEGAVEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; COLITIS; FATTY ACIDS, OMEGA-3; INFLAMMATION; MALE; MESALAMINE; NF-KAPPA B; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; TRINITROBENZENESULFONIC ACID;

RATTUS;

EID: 84875072990     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.03.022     Document Type: Article

References (40)

1. Iacucci M., de Silva S., Ghosh S. Mesalazine in inflammatory bowel disease: a trendy topic once again?. Can J Gastroenterol 2010, 24(2):127-133.
2. Bantel H., Berg C., Vieth M., Stolte M., Kruis W., Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000, 95(12):3452-3457.
3. Collier H.O., Francis A.A., McDonald-Gibson W.J., Saeed S.A. Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites. Prostaglandins 1976, 11(2):219-225.
4. Sharon P., Ligumsky M., Rachmilewitz D., Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978, 75(4):638-640.
5. Horvath K., Varga C., Berko A., Posa A., Laszlo F., Whittle B.J. The involvement of heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid in rat colitis. Eur J Pharmacol 2008, 581(3):315-323.
6. Reifen R., Nissenkorn A., Matas Z., Bujanover Y. 5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis. J Gastroenterol 2004, 39(6):514-519.
7. Park K., Perez F., Tsai R., Honkanen A., Bass D., Garber A. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2011.
8. Holt P.R., Katz S., Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005, 50(11):2191-2193.
9. Henriksen C., Hansen S., Nordgaard-Lassen I., Anderson J.R., Madsen P. Possible interactions between dietary fibres and 5-aminosalicyclic acid. Therap Adv Gastroenterol 2011, 3(1):5-9.
10. Tursi A., Brandimarte G., Giorgetti G.M., Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006, 40(4):312-316.
11. Ukil A., Maity S., Karmakar S., Datta N., Vedasiromoni J.R., Das P.K. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003, 139(2):209-218.
12. Binion D.G., Heidemann J., Li M.S., Nelson V.M., Otterson M.F., Rafiee P. Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am J Physiol Gastrointest Liver Physiol 2009, 297(2):G259-G268.
13. Salh B., Assi K., Templeman V., Parhar K., Owen D., Gomez-Munoz A., et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 2003, 285(1):G235-G243.
14. Papadia C., Coruzzi A., Montana C., Di Mario F., Franze A., Forbes A. Omega-3 fatty acids in the maintenance of ulcerative colitis. JRSM Short Rep 2010, 1(1).
15. Hassan A., Ibrahim A., Mbodji K., Coeffier M., Ziegler F., Bounoure F., et al. An alpha-linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NF-kappaB in rats with TNBS-induced colitis. J Nutr 2010, 140(10):1714-1721.
16. Ibrahim A., Aziz M., Hassan A., Mbodji K., Collasse E., Coeffier M., et al. Dietary alpha-linolenic acid-rich formula reduces adhesion molecules in rats with experimental colitis. Nutrition 2012.
17. Ibrahim A., Mbodji K., Hassan A., Aziz M., Boukhettala N., Coeffier M., et al. Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium. Clin Nutr 2011, 30(5):678-687.
18. Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-{gamma}. J Exp Med 2005, 201(8):1205-1215.
19. Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001, 193(7):827-838.
20. Dubuquoy L., Rousseaux C., Thuru X., Peyrin-Biroulet L., Romano O., Chavatte P., et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006, 55(9):1341-1349.
21. Marion-Letellier R., Dechelotte P., Iacucci M., Ghosh S. Dietary modulation of peroxisome proliferator-activated receptor gamma. Gut 2009, 58(4):586-593.
22. Marion-Letellier R., Butler M., Dechelotte P., Playford R.J., Ghosh S. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells-potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. Am J Clin Nutr 2008, 87(4):939-948.
23. Charpentier C., Marion-Letellier R., Savoye G., Nicol L., Mulder P., Aziz M., et al. Magnetic resonance colonography in rats with TNBS-induced colitis: a feasibility and validation study. Inflamm Bowel Dis 2012.
24. Song M., Xia B., Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad Med J 2006, 82(964):130-135.
25. Ancha H.R., Kurella R.R., McKimmey C.C., Lightfoot S., Harty R.F. Effects of N-acetylcysteine plus mesalamine on prostaglandin synthesis and nitric oxide generation in TNBS-induced colitis in rats. Dig Dis Sci 2009, 54(4):758-766.
26. Romano C., Cucchiara S., Barabino A., Annese V., Sferlazzas C. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol 2005, 11(45):7118-7121.
27. Papadia C., Coruzzi A., Montana C., Di Mario F., Franze A., Forbes A. Omega-3 fatty acids in the maintenance of ulcerative colitis. JRSM Short Rep 2010, 1(1):15.
28. Deng X., Tolstanova G., Khomenko T., Chen L., Tarnawski A., Szabo S., et al. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine. J Pharmacol Exp Ther 2009, 331(3):1071-1078.
29. Henriksen C., Hansen S., Nordgaard-Lassen I., Anderson J.R., Madsen P. Possible interactions between dietary fibres and 5-aminosalicyclic acid. Therap Adv Gastroenterol 2010, 3(1):5-9.
30. Hegazi R.A.F., Saad R.S., Mady H., Matarese L.E., O'Keefe S., Kandil H.M. Dietary fatty acids modulate chronic colitis, colitis-associated colon neoplasia and COX-2 expression in IL-10 knockout mice. Nutrition 2006, 22(3):275-282.
31. Matsunaga H., Hokari R., Kurihara C., Okada Y., Takebayashi K., Okudaira K., et al. Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts. Inflamm Bowel Dis 2008, 14(10):1348-1357.
32. Woodworth H.L., McCaskey S.J., Duriancik D.M., Clinthorne J.F., Langohr I.M., Gardner E.M., et al. Dietary fish oil alters t lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis. Cancer Res 2010, 70(20):7960-7969.
33. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999, 104(4):383-389.
34. Desreumaux P., Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther 2006, 24(Suppl. 1):2-9.
35. Aoyagi Y., Nagata S., Kudo T., Fujii T., Wada M., Chiba Y., et al. Peroxisome proliferator-activated receptor gamma 2 mutation may cause a subset of ulcerative colitis. Pediatr Int 2010, 52(5):729-734.
36. Hedin C.R.H., Mullard M., Sharratt E., Jansen C., Sanderson J.D., Shirlaw P., et al. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2010, 16(12):2099-2108.
37. Uchiyama K., Nakamura M., Odahara S., Koido S., Katahira K., Shiraishi H., et al. N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis 2010, 16(10):1696-1707.
38. Grimstad T., Berge R.K., Bohov P., Skorve J., Goransson L., Omdal R., et al. Salmon diet in patients with active ulcerative colitis reduced the simple clinical colitis activity index and increased the anti-inflammatory fatty acid index - a pilot study. Scand J Clin Lab Invest 2011, 71(1):68-73.
39. Stolfi C., Fina D., Caruso R., Caprioli F., Sarra M., Fantini M.C., et al. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 2008, 75(3):668-676.
40. Cockbain A.J., Toogood G.J., Hull M.A. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut 2011, 61(1):135-149.